Antibacterial Drugs

ORBACTIV ® (oritavancin) Orbactiv ® (oritavancin) is a semisynthetic lipoglycopeptide antibacterial drug. It exerts concentration-dependent bactericidal activity in vitro against S. aureus, S. pyogenes, and E. faecalis . Orbactiv ® is specifically indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: • Staphylococcus aureus (including methicillin-susceptible and methicillin–resistant isolates) • Streptococcus pyogenes • Streptococcus agalactiae • Streptococcus dysgalactiae • Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus) • Enterococcus faecalis (vancomycin-susceptible isolates only) Orbactiv ® is supplied as a solution for intravenous infusion. The recommended dose is a single 1200 mg dose administered by intravenous infusion over three hours in patients 18 years and older. DALVANCE ® (dalbavancin) Dalvance ® (dalbavancin) is a lipoglycopeptide antibacterial drug proposed for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: • Staphylococcus aureus (including methicillin-resistant [MRSA] isolates) • Streptococcus pyogenes • Streptococcus agalactiae • Streptococcus anginosus group (including S. anginosus, S. intermedius, S. constellatus) • Enterococcus faecalis (vancomycin-susceptible isolates only) Because of its long elimination half-life, the dosing regimen is 1000 mg on Day 1 and 500 mg on Day 8, administered intravenously (IV) over 30 minutes. VIBATIV ® (telavancin) Vibativ ® (telavancin) is a bactericidal, once-daily, injectable lipoglycopeptide antibiotic with a dual mechanism of action whereby Vibativ both inhibits bacterial cell wall synthesis and disrupts bacterial cell membrane function. Vibativ ® is specifically indicated for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: • Staphylococcus aureus (including methicillin-susceptible and -resistant isolates) • Streptococcus pyogenes • Streptococcus agalactiae • Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus) • Enterococcus faecalis (vancomycin-susceptible isolates only) • Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Staphylococcus aureus . Vibativ ® is supplied as a powder for reconstitution onto a solution designed for intravenous administration. The recommended initial dose is 10 mg/kg administered over a 60-minute period in patients >18 years of age by intravenous infusion once every 24 hours for 7 to 14 days. SIVEXTRO ® ( tedizolid) Sivextro ® (tedizolid) is an oxazolidinone-class antibacterial drug indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: • Staphylococcus aureus (including methicillin-susceptible and methicillin–resistant isolates) • Streptococcus pyogenes • Streptococcus agalactiae • Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus) • Enterococcus faecalis (vancomycin-susceptible isolates only). The recommended dosage is 200 mg administered once daily for 6 days. Sivextro ® can be given orally (with or without food) or as an intravenous (IV) infusion over 1 hour for patients 18 years of age or older. To reduce the development of drug-resistant bacteria and maintain the effectiveness of these drugs-oritavancin, dalbavancin, telavancin and tedizolid should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.